📊 BDTB Key Takeaways
Is Bodhi Tree Biotechnology Inc (BDTB) a Good Investment?
Bodhi Tree Biotechnology is a pre-revenue shell company with severe operational losses and negative cash flow, indicating it is not yet a functioning business. The company is rapidly burning cash despite minimal operations, with negative ROE and ROA suggesting shareholder value destruction. Without demonstrated revenue generation capability or clear path to profitability, this represents a speculative investment with substantial going concern risk.
Bodhi Tree Biotechnology Inc shows extremely weak fundamentals: it generated no meaningful revenue, remains unprofitable, and consumed cash through operations with negative free cash flow. While the balance sheet has minimal liabilities, the company is very small, equity is being eroded by ongoing losses, and there is no evidence yet of sustainable operating traction or high-quality growth.
Why Buy Bodhi Tree Biotechnology Inc Stock? BDTB Key Strengths
- Positive stockholders equity of $66.2K provides minimal equity cushion
- Low debt burden with zero long-term debt reduces leverage risk
- Cash position of $47.4K provides short-term runway for operations
- Very low leverage with only $3.50K of liabilities and effectively no debt burden
- Positive stockholders' equity of $66.21K provides a limited balance-sheet cushion
- Cash of $47.37K exceeds liabilities, reducing immediate solvency pressure
BDTB Stock Risks: Bodhi Tree Biotechnology Inc Investment Risks
- Zero revenue generation with no demonstrated business model or market traction
- Negative operating cash flow of -$62K indicates unsustainable cash burn rate
- Severely negative returns on equity (-80%) and assets (-76%) demonstrating value destruction
- Pre-revenue status suggests high risk of failure and capital depletion within 12-18 months at current burn rate
- No insider activity in past 90 days indicates lack of management confidence
- No real revenue base, making the reported growth figure low quality and not indicative of operating momentum
- Persistent net losses and negative operating cash flow indicate the business is not self-funding
- Tiny asset and cash base creates significant execution and liquidity risk if losses continue
Key Metrics to Watch
- Revenue generation and path to profitability
- Monthly cash burn rate and runway remaining
- Operating cash flow trend and improvement toward breakeven
- Form 4 filings indicating insider buying confidence
- Sustainable revenue generation and whether sales become recurring and material
- Operating cash burn relative to cash on hand and resulting equity erosion
Bodhi Tree Biotechnology Inc (BDTB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BDTB Profit Margin, ROE & Profitability Analysis
BDTB vs Services Sector: How Bodhi Tree Biotechnology Inc Compares
How Bodhi Tree Biotechnology Inc compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bodhi Tree Biotechnology Inc Stock Overvalued? BDTB Valuation Analysis 2026
Based on fundamental analysis, Bodhi Tree Biotechnology Inc has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bodhi Tree Biotechnology Inc Balance Sheet: BDTB Debt, Cash & Liquidity
BDTB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bodhi Tree Biotechnology Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
BDTB Revenue Growth, EPS Growth & YoY Performance
BDTB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$52.9K | $0.00 |
| Q3 2025 | $5.0K | $9.6K | $0.00 |
| Q2 2025 | $5.0K | -$116 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bodhi Tree Biotechnology Inc Dividends, Buybacks & Capital Allocation
BDTB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bodhi Tree Biotechnology Inc (CIK: 0002041531)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDTB
What is the AI rating for BDTB?
Bodhi Tree Biotechnology Inc (BDTB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDTB's key strengths?
Claude: Positive stockholders equity of $66.2K provides minimal equity cushion. Low debt burden with zero long-term debt reduces leverage risk. ChatGPT: Very low leverage with only $3.50K of liabilities and effectively no debt burden. Positive stockholders' equity of $66.21K provides a limited balance-sheet cushion.
What are the risks of investing in BDTB?
Claude: Zero revenue generation with no demonstrated business model or market traction. Negative operating cash flow of -$62K indicates unsustainable cash burn rate. ChatGPT: No real revenue base, making the reported growth figure low quality and not indicative of operating momentum. Persistent net losses and negative operating cash flow indicate the business is not self-funding.
What is BDTB's revenue and growth?
Bodhi Tree Biotechnology Inc reported revenue of $0.0.
Does BDTB pay dividends?
Bodhi Tree Biotechnology Inc does not currently pay dividends.
Where can I find BDTB SEC filings?
Official SEC filings for Bodhi Tree Biotechnology Inc (CIK: 0002041531) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDTB's EPS?
Bodhi Tree Biotechnology Inc has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BDTB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bodhi Tree Biotechnology Inc has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BDTB stock overvalued or undervalued?
Valuation metrics for BDTB: ROE of -80.0% (sector avg: 16%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BDTB stock in 2026?
Our dual AI analysis gives Bodhi Tree Biotechnology Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDTB's free cash flow?
Bodhi Tree Biotechnology Inc's operating cash flow is $-62.0K, with capital expenditures of N/A.
How does BDTB compare to other Services stocks?
Vs Services sector averages: Net margin N/A (avg: 10%), ROE -80.0% (avg: 16%), current ratio N/A (avg: 1.5).